Rivaroxaban for preventing adverse outcomes after acute management of acute coronary

blood pressure, haematoma, stomach pain, dyspepsia (heartburn), nausea, constipation, diarrhoea, vomiting, pruritus (itching), rash, bruising, pain in the extremities, fever, and swelling, especially of the ankles and feet. For full details of adverse reactions and contraindications, see the summary of product characteristics. 2.4 The list price of rivaroxaban is £58.88 per 2.5 mg, 56 capsule pack (excluding VAT, company submission) The recommended dose is 2.5 mg twice daily which equates to a price of £2.10 per day. Total acquisition costs depend on the duration of therapy. Assuming a treatment duration of 12 months, total acquisition costs are £766.50. Costs may vary in different settings because of negotiated procurement discounts. 3 The company's submission The Appraisal Committee considered evidence submitted by the company that manufactures rivaroxaban and a review of this submission by the Evidence Review Group (ERG). 3.1 The main evidence in the company's submission came from ATLAS-ACS 2-TIMI 51. This was an international, multicentre (766 sites in 44 countries including the UK), randomised controlled trial (RCT) designed to evaluate whether rivaroxaban in addition to standard-care antiplatelet therapy reduced the risk of cardiovascular death, myocardial infarction or stroke in patients with recent acute coronary syndrome (unstable angina, non-ST segment elevation
